Clostridioides difficile Infection (Adult)

1. Overview

Clostridioides difficile Infection (CDI) is a toxin-mediated colonic disease caused by an anaerobic, Gram-positive, spore-forming bacillus. It is the leading cause of healthcare-associated infectious diarrhoea and represents a significant threat to global health security due to the emergence of hypervirulent strains (e.g., ribotype 027). [1]

The clinical spectrum of CDI ranges from mild, self-limiting diarrhoea to life-threatening pseudomembranous colitis, toxic megacolon, and fulminant sepsis. The pathophysiology is fundamentally rooted in the disruption of the gut's normal "colonisation resistance" — typically by broad-spectrum antibiotics — allowing C. difficile to germinate and release potent cytotoxins. [2]

Management has shifted dramatically in the 2020 s: Fidaxomicin is now the preferred first-line agent over Vancomycin for many due to lower recurrence rates, and Faecal Microbiota Transplantation (FMT) (including the new oral encapsulated products) has become the standard of care for multiply recurrent disease. [3]

2. Epidemiology

Global Prevalence

• Stats: CDI causes approximately 500,000 infections and 30,000 deaths annually in the United States alone.
• The Community Shift: Once strictly a hospital-acquired infection (HAI), up to 35% of cases are now community-acquired (CA-CDI), often affecting younger, "low-risk" individuals without prior antibiotic exposure. [4]

The "4 Cs" Antibiotic Risk

While any antibiotic can trigger CDI, the "4 Cs" remain the primary drivers in board examinations:

1. Clindamycin (Highest risk per dose).
2. Ciprofloxacin (and other quinolones).
3. Cephalosporins (specifically 2nd and 3rd generation).
4. Co-amoxiclav (and broad-spectrum penicillins).

---

3. Aetiology & Pathophysiology

⚠️ THE 7-STEP MOLECULAR MECHANISM

1. Microbiome Depletion: Broad-spectrum antibiotics deplete the "commensal shield" (specifically Bacteroidetes and Firmicutes). This reduces the conversion of primary to secondary bile acids (which normally inhibit C. diff growth).
2. Spore Germination: Ingested spores survive the stomach's acid (facilitated by PPIs). In the small intestine, bile salts (taurocholate) trigger germination into the vegetative, toxin-producing form.
3. Adhesion & Colonisation: C. diff uses Surface Layer Proteins (Slps) and fimbriae to adhere to the colonic mucosa.
4. Toxin Release (TcdA and TcdB): Large clostridial toxins are released. TcdB is the most essential for virulence, being 1000x more potent than TcdA.
5. Rho-GTPase Glucosylation: Toxins enter enterocytes via endocytosis. The enzymatic domain glues a glucose molecule onto Rho, Rac, and Cdc42 GTPases. This "locks" the molecular switches in the 'off' position.
6. Cytoskeletal Collapse: Inactivation of Rho-GTPases leads to the breakdown of the actin cytoskeleton and disruption of tight junctions (zonula occludens).
7. Inflammation & Pseudomembrane Formation: The resulting epithelial cell death triggers a massive influx of neutrophils (Pus). The combination of fibrin, mucus, and dead cells creates the yellow-white Pseudomembranes characteristic of severe disease. [5, 6]

---

4. Clinical Presentation

Symptoms

• Diarrhoea: Typically watery, non-bloody (unless severe), and has a characteristic "barn-like" or "horse-manure" odour.
• Abdominal Pain: Diffuse cramping.
• The "Ileus Mask": In fulminant disease, diarrhoea may stop as the colon dilates and loses motility (Toxic Megacolon).

Severity Stratification (NICE/IDSA)

---

5. Investigations

The 2-Step Testing Algorithm

1. GDH (Glutamate Dehydrogenase): Highly sensitive screening test (detects the organism, not the toxin). If negative, CDI is ruled out.
2. Toxin EIA: Specific test to detect free toxin (proves active disease).
3. NAAT (PCR): Used to resolve discordance. If NAAT is positive but Toxin EIA is negative, the patient may be a colonised carrier rather than having active CDI. [7]

Imaging

• Abdominal X-Ray: Essential to measure the transverse colon. > 6cm indicates Toxic Megacolon.
• CT Abdomen: Shows "Accordion Sign" (diffuse colonic wall thickening and thumbprinting).

---

6. Management: The Modern Protocol

1. First Episode (Non-Fulminant)

• Preferred: Fidaxomicin 200mg BD for 10 days. (Evidence: Reduced recurrence compared to Vancomycin).
• Alternative: Oral Vancomycin 125mg QDS for 10 days.
• Obsolete: Oral Metronidazole is no longer recommended for adults due to high failure rates. [8]

2. Fulminant CDI (The "Triple" Strategy)

1. High-dose Oral Vancomycin (500mg QDS).
2. Rectal Vancomycin Enemas (if ileus is present).
3. IV Metronidazole (500mg TDS). (The only role for IV therapy).

3. Recurrent CDI & FMT

• Bezlotoxumab: A monoclonal antibody against Toxin B; given as a single IV dose during antibiotic therapy to prevent recurrence.
• FMT: Indicated for the 2nd or 3rd recurrence. Success rates > 90%.
• New (2024): Vowst (SER-109) - FDA-approved oral microbial spores for preventing recurrence. [9]

---

7. Evidence: Landmark Trials

---

8. Single Best Answer (SBA) Questions

Question 1

An 80-year-old male with Stage 3 CKD is diagnosed with severe CDI (WCC 18, Cr 1.5x baseline). He is on his first episode. What is the most appropriate first-line treatment?

• A) Oral Metronidazole 400mg TDS
• B) Oral Vancomycin 125mg QDS
• C) Oral Fidaxomicin 200mg BD
• D) IV Vancomycin 1g BD
• E) FMT via nasogastric tube
• Answer: C. Per 2021-2024 updates (IDSA and NICE), Fidaxomicin is now preferred for severe or high-risk first episodes to prevent the cycle of recurrence.

Question 2

What is the molecular mechanism of C. difficile Toxin B (TcdB) within the colonic enterocyte?

• A) Cleavage of SNAP-25
• B) ADP-ribosylation of G-proteins
• C) Glucosylation of Rho-GTPases
• D) Inhibition of the 50S ribosomal subunit
• E) Activation of adenylate cyclase
• Answer: C. TcdB is a glucosyltransferase that inactivates Rho-family proteins, leading to cytoskeletal collapse and cell death.

---

9. Viva Scenario: The "Diarrhoea-less" Surgical Emergency

Examiner: "A patient with known CDI suddenly stops having diarrhoea, but their abdomen is now distended and tender. Their WCC is 30 and lactate is 4. What is the diagnosis and your next step?"

Candidate:

1. Diagnosis: This is Toxic Megacolon complicating CDI. The cessation of diarrhoea is an ominous sign of paralytic ileus and colonic exhaustion.
2. Emergency Imaging: I would order an immediate Plain Abdominal X-Ray to look for colonic dilatation > 6cm.
3. Management: I would escalate to the surgical team and ICU. This patient likely requires a Subtotal Colectomy with end-ileostomy.
4. Rationale: Delaying surgery in toxic megacolon when lactate is rising or WCC is > 25 is associated with near-total mortality. [10]

---

10. Patient Explanation

"C. diff is a stubborn germ that lives in the gut. Normally, your healthy bacteria keep it 'locked away.' When you take antibiotics, it's like opening the cage door—the C. diff grows out of control and releases toxins that damage the lining of your bowel. This is why you have severe diarrhoea. We are giving you a specific antibiotic (like Fidaxomicin) that acts like a heat-seeking missile for this germ. It's also vital you wash your hands with soap and water, as the alcohol gel doesn't kill the C. diff 'seeds' (spores)."

---

11. References

1. McDonald LC, et al. Clinical Practice Guidelines for C. difficile Infection (IDSA/SHEA). Clin Infect Dis. 2018. [PMID: 29462280]
2. Johnson S, et al. IDSA/SHEA 2021 Focused Update on Management of CDI. Clin Infect Dis. 2021. [PMID: 34164674]
3. Van Nood E, et al. Duodenal Infusion of Donor Feces for Recurrent CDI. N Engl J Med. 2013. [PMID: 23323867]
4. Louie TJ, et al. Fidaxomicin versus Vancomycin for CDI. N Engl J Med. 2011. [PMID: 21288078]
5. Feuerstadt P, et al. SER-109, an Oral Microbiome Therapy for Recurrent CDI (ECOSPOR-III). N Engl J Med. 2022. [PMID: 35044802]

---

Last Updated: 2026-01-05 | MedVellum Editorial Team